GA
ATHE

Geneva Advisors’s Alterity Therapeutics ATHE Stock Holding History

Geneva Advisors’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-184
Closed -$24K – 711
2014
Q3 		$24K Buy
+184
New +$24.6K ﹤0.01% 674

Other funds holding ATHE

VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CAM
Columbia Asset Management Ann Arbor, Michigan $575M AUM 29.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Geneva Advisors's ATHE Position: Q4 2014 in Review

Geneva Advisors sold out of Alterity Therapeutics (ATHE) in Q4 2014, closing a stake of 184 shares — an estimated $24K sold.

Geneva Advisors first reported a position in ATHE in Q3 2014 and held it in 1 quarter. The position peaked at $24K in Q3 2014. 24 funds tracked by Wall St. Rank hold ATHE as of Q4 2014.

  • Geneva Advisors reported no remaining Alterity Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Geneva Advisors sold 184 Alterity Therapeutics shares in Q4 2014, an estimated $24K.
  • Geneva Advisors first reported a position in Alterity Therapeutics in Q3 2014 and held it in 1 quarter.
  • Geneva Advisors's Alterity Therapeutics position peaked at $24K in Q3 2014.
  • 24 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q4 2014.

Based on Geneva Advisors's 13F filing for Q4 2014, filed 2 Feb 2015.